



AsymBio's Services for Early-Stage Drug Development

Transient Expression (CHO-K1)

*Timeline includes expression, purification and quality tests.

Scale	Method	Titer	Timeline*	Purification	Throughput	Quality Test
µg~mg	Well plates	~500 mg/L	2 weeks	Membrane purification	96 molecules per batch	A280, SEC-HPLC SDS-PAGE (Optional)
mg~g	Spin tubes	~2 g/L	2 weeks	Gravity chromatography	10 molecules per batch	iCIEF, CE-SDS (Optional)
g	Flasks	~6 g/L	5 weeks	AKTA	3 molecules per batch	

Sample Preparation for Bioconjugates

* Timeline includes ADC preparation and required quality tests , preparation for mAb and L-P is not included.

Scale	Method	Titer	Timeline*	Purification	Throughput	Quality Test
1~10mg	EP tube	1~2	1~2w	Desalting columns	10+	DAR, SEC, protein concentration (Required)
100mg	Glass flasks	2	2W	Ultrafiltration tubes	2~3	Free-drug, endotoxin, Binding activities (optional)
1~10g	Reactors	3	3W	Cassettes	1	

Payload-linker Catalog Products

vcMMAE	CL2A-SN38	mcMMAF	Tesirine	MC-GGFG-DXd	SPBDDM4
MC-GGFG-Exatecan	SMCC-DM 1	MC-β-Glucuronide -MMAF	MC-β-Glucuronide -Exatecan	DBC0-PEG3-VC -Exatecan	Mal-PEG2-Val -Cit-PAB-eribulin

Antibody Inventory for ADCs

* Ready-to-use plasmids for antibody inventory

* 1 week timeline for >100 mg sample preparation

Drug	Target	Drug	Target	Drug	Target	Drug	Target
CMG901	CLDN18.2	MRG003	EGFR	Mylotarg	CD33	Blenrep	BCMA
IBI343	CLDN18.2	STRO-002	EGFR	Adcetris	CD30	Trodelyv	Trop-2
LM-302	CLDN18.2	Zilovertamab vedotin	ROR1	Kadcyla	HER2	Akalux	EGFR
DS-7300	B7-H3			Besponsa	CD22	Zynlonta	CD19
DB-1311	B7-H3	Telisotuzumab vedotin	c-MET	Lumoxiti	CD22	Aidixi	HER2
Patritumab deruxtecan	HER3			Enhertu	HER2	Elahere	FRα
		HDP-101	DLL3	Padcev	Nectin-4	sac-TMT	Trop-2
				Tivdak	TF	DS-1062	Trop-2


Developability Evaluation

Advanced platform for material preparation

Systematic evaluation

Rich experience on various DP dosage forms

Multiple Modalities



Customized stress studies



Featured developability evaluation

- Lead molecule screen
- Formulation developability
- Stability indicating CQA identification
- Degradation pathway understanding

Highly recommended for new modalities or special molecules

Stress study for production, storage and transportation conditions

Bridging between discovery and CMC early development stages

Developability Evaluation Service Scope

Study	Condition	Time	Appearance	pH	Protein Conc.	T _m & T _{agg}	Purity				ADC related	
							SEC	iCIEF/CEX	CE		e.g. DAR	
									NR	R		
Thermal	Reference	T0	*	*	*	*	*	*	*	*	*	
		40°C	T1W	*	*	*	N/A	*	*	*	*	*
			T2W	*	*	*	N/A	*	*	*	*	*
			T4W	*	*	*	N/A	*	*	*	*	*
	25°C	T2W	*	*	*	N/A	*	*	*	*	*	
		T4W	*	*	*	N/A	*	*	*	*	*	
Shaking	Xrpm@RT	1Day	*	*	*	N/A	*	*	*	*	*	
		3Day	*	*	*	N/A	*	*	*	*	*	
Freeze-Thaw	-X°C to RT	1Cycle	*	*	*	N/A	*	*	*	*	*	
		3Cycle	*	*	*	N/A	*	*	*	*	*	
Low pH	e.g. ≤4.0	T0	*	*	*	N/A	*	*	*	*	*	
		Tend	*	*	*	N/A	*	*	*	*	*	
High pH	e.g. ≥8.0	T0	*	*	*	N/A	*	*	*	*	*	
		Tend	*	*	*	N/A	*	*	*	*	*	
Light	25°C	X*ICH	*	*	*	N/A	*	*	*	*	*	
		Y*ICH	*	*	*	N/A	*	*	*	*	*	
Oxidant	H ₂ O ₂	X%-Ahr	*	*	*	N/A	*	*	*	*	*	
		X%-Bhr	*	*	*	N/A	*	*	*	*	*	

*Note: grey for basic package; blue for optional package